Cost Utility Analysis

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

Could cemiplimab reshape cervical cancer care — and what does that mean for access and value? 🔬 This article unpacks the clinical benefits seen in recent studies, the pricing and reimbursement hurdles limiting patient access, and pragmatic value-based strategies (e.g., managed entry agreements, budget impact framing) for payers and policymakers. Read the full analysis to learn how stakeholders can balance innovation with affordability and improve real-world access. 💡 #SyenzaNews #oncology #HealthEconomics #MarketAccess #costeffectiveness

🩺 Could we finally delay the onset of Type 1 diabetes? NICE has recommended teplizumab for people at high risk (stage 2), marking a potential first disease‑modifying option that can postpone progression to clinical disease — a decision driven by trial benefit, patient selection and cost‑effectiveness considerations. Read the full #SyenzaNews analysis to understand what this means for clinicians, payers and patients — and how implementation might unfold. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

Is cancer quietly draining productivity across Asia‑Pacific? 💼📉 This analysis highlights large productivity losses driven by late diagnosis, unequal access to treatment, and weak return‑to‑work support — with sharp disparities between countries and industries. Tackling screening, survivorship care and employer‑led reintegration could recover economic value and improve patient outcomes. Read the full article for country comparisons and practical policy and employer actions. #SyenzaNews #oncology #HealthEconomics #healthcarepolicy #resourceallocation

Could a topical cream reshape care for facial vitiligo? 🧴 NICE has recommended ruxolitinib cream as a treatment option for facial vitiligo — a regulatory milestone that could improve repigmentation outcomes and patient access in the UK. This decision matters for dermatologists, payers and manufacturers navigating evidence, eligibility and reimbursement. Read the full article for the clinical rationale and market-access implications. #SyenzaNews #pharmaceuticals #regulatoryaffairs #healthcarepolicy #MarketAccess

Could a reimbursement rejection for lecanemab change the future of Alzheimer’s care in Europe? 🧠⚖️ Zorginstituut’s refusal to reimburse lecanemab highlights the clash between uncertain clinical benefit and high price, affecting patients, payers, and pharma market-access strategies. The article breaks down the HTA rationale, economic implications, and lessons for pricing and evidence generation for dementia therapies. Read the full analysis to see what this decision means for stakeholders and next steps in Alzheimer’s drug access. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Could NICE’s endorsement unlock broader access to pegzilarginase for people with arginase deficiency? NICE has recommended pegzilarginase after reviewing clinical evidence that shows meaningful metabolic and functional benefits, a pivotal step for this rare urea-cycle disorder that also shapes reimbursement and adoption pathways. Read the full article to understand the clinical data, cost-effectiveness considerations, and what this means for patients, clinicians, and market access teams. 🔍 #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #healthcarepolicy

Are your clinical studies ready for EU-wide HTA alignment? The European Commission has opened the first 2026 submission window for Joint Scientific Consultations (Jan 7–Feb 4, 2026) — a free opportunity to get early HTA input (including parallel EMA coordination) that helps design studies fit for Joint Clinical Assessments and smoother market access. Aligning evidence early can cut duplication, reduce assessment delays, and strengthen reimbursement cases. Read the full article to see key deadlines, submission steps, and practical tips to make the most of JSCs. 🔗 #SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬 NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding improved event‑free and overall survival versus blinatumomab, inotuzumab and ponatinib and cost‑effectiveness within NHS thresholds — though it’s not recommended for 18–25s due to pricing vs tisagenlecleucel. Read the full guidance to see what this means for clinicians, payers and developers. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

🌟 Can innovative therapies redefine the landscape of metastatic triple-negative breast cancer treatment? Recent findings from the TROPION-Breast02 trial reveal that Datroway TNBC therapy delivers significant improvements in overall and progression-free survival for patients unable to access immunotherapy. This groundbreaking development not only addresses a critical unmet medical need but also sets a new precedent in cancer care. Dive into the remarkable impacts of this first-in-class therapy and its implications for market access and health economics. #SyenzaNews #oncology #MarketAccess 🩺

💡 How do we balance innovative therapies with healthcare budgets? In the recent ACP124 meeting, the Adviescommissie Pakket tackled critical decisions regarding reimbursements for two groundbreaking orphan drugs. This discussion emphasized the ongoing challenges of health technology assessment (HTA) in ensuring patient access while maintaining system sustainability. Explore how decision-makers are navigating the delicate interplay between clinical value and cost-effectiveness in healthcare. #SyenzaNews #HealthTechnology #HealthEconomics #MarketAccess

🌟 Are you ready for a transformation in pharmacoeconomic assessments? The Dutch National Health Care Institute is set to unveil its **Pharmacoeconomic Redesign** on September 1, 2025, introducing a refined framework for evaluating drug reimbursement in the Netherlands. This innovative approach emphasizes clarity, transparency, and methodological rigor, ensuring more informed decisions in healthcare. Dive into the article to discover how these changes will impact market access and elevate standards in health economics! #SyenzaNews #HealthEconomics #MarketAccess